Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.70 |
| ▸ | LPL | P06858 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670134 | 1.00 | LIPG (0.70) | LIPGLPLENPP2HTR1ALIPE | |
| SCHEMBL29948801 | 0.86 | LIPG (0.85) | LIPGLPLCA1CA2PCSK9 | |
| SCHEMBL1128560 | 0.86 | LIPG (0.85) | LIPGLPLCA1CA2PCSK9 | |
| SCHEMBL28592623 | 0.86 | LIPG (0.55) | LIPGLPLENPP2HTR1ALIPE | |
| SCHEMBL747937 | 0.85 | LIPG (0.96) | LIPGLPL | |
| SCHEMBL29670235 | 0.85 | LIPG (0.96) | LIPGLPL | |
| SCHEMBL29845752 | 0.84 | LIPG (0.62) | LIPGLPLENPP2HTR1ALIPE | |
| SCHEMBL2560981 | 0.84 | LIPG (0.62) | LIPGLPLENPP2HTR1ALIPE | |
| SCHEMBL15745852 | 0.84 | LIPG (0.88) | LIPGLPLENPP2 | |
| SCHEMBL410387 | 0.83 | LIPG (0.61) | LIPGLPLENPP2LIPEPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751203-A | Synthetic method of substituent-containing naphthalene ring liquid crystal monomer | 江苏广域化学有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-12509415-B2 | Compounds, liquid compositions including compounds, and electroluminescent devices | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-12-30 | — | — | US | disclosed |
| CN-119751203-A | Synthetic method of substituent-containing naphthalene ring liquid crystal monomer | 江苏广域化学有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119751203-A | Synthetic method of substituent-containing naphthalene ring liquid crystal monomer | 江苏广域化学有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-108368070-B | Polymerizable compound and optically anisotropic body | DIC株式会社 | 2023-04-28 | — | — | CN | disclosed |
| US-20220213022-A1 | COMPOUNDS, LIQUID COMPOSITIONS INCLUDING COMPOUNDS, AND ELECTROLUMINESCENT DEVICES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
| CN-111778040-B | Liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3931180-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-108753312-B | Liquid crystal compound, preparation method thereof, composition containing liquid crystal compound and high-frequency component containing liquid crystal medium | 西安近代化学研究所 | 2021-07-27 | — | — | CN | disclosed |
| CN-112851562-A | Aromatic ring liquid crystal compound, liquid crystal composition and application thereof | 烟台显华化工科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007119434-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF AS HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-25 | — | — | WO | disclosed |
| EP-1763902-A2 | STABLE AND EFFICIENT ELECTROLUMINESCENT MATERIALS | Universal Display Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006014599-A2 | STABLE AND EFFICIENT ELECTROLUMINESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | disclosed |
| EP-1565466-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509415-B2 | Compounds, liquid compositions including compounds, and electroluminescent devices | MLLT3, MLLT1, BMI1 | LIPG 1641/4885LPL 2661/4885ENPP2 3010/4885 |
| US-20220213022-A1 | COMPOUNDS, LIQUID COMPOSITIONS INCLUDING COMPOUNDS, AND ELECTROLUMINESCENT DEVICES | ETV6, ELANE, XPOT | LIPG 2264/4885LPL 3060/4885ENPP2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.